Article Text

Download PDFPDF

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial
  1. J N Gordon,
  2. T M Trebble,
  3. R D Ellis,
  4. H D Duncan,
  5. T Johns,
  6. P M Goggin
  1. Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth, UK
  1. Correspondence to:
    Dr J N Gordon
    Mailpoint 813, Level E, South Block, Southampton General Hospital, Southampton SO16 6YD, UK; j.gordonsoton.ac.uk

Abstract

Background: Proinflammatory cytokines, especially tumour necrosis factor α (TNF-α), play a prominent role in the pathogenesis of cancer cachexia. Thalidomide, which is an inhibitor of TNF-α synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.

Aims: To assess the safety and efficacy of thalidomide in attenuating weight loss in patients with cachexia secondary to advanced pancreatic cancer.

Methods: Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial. The primary outcome was change in weight and nutritional status.

Results: Thirty three patients (16 control, 17 thalidomide) were evaluated at four weeks, and 20 patients (eight control, 12 thalidomide) at eight weeks. At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm3 in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference −2.59 kg (95% confidence interval (CI) −4.3 to −0.8); p = 0.005) and 4.46 cm3 (absolute difference −5.6 cm3 (95% CI −8.9 to −2.2); p = 0.002) in the placebo group. At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm3 in AMA compared with a loss of 3.62 kg (absolute difference −3.57 kg (95% CI −6.8 to −0.3); p = 0.034) and 8.4 cm3 (absolute difference −7.9 cm3 (95% CI −14.0 to −1.8); p = 0.014) in the placebo group. Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).

Conclusion: Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.

  • TNF, tumour necrosis factor
  • IL, interleukin
  • IFN, interferon
  • PIF, proteolysis inducing factor
  • NFκB, nuclear factor κB
  • IκB, inhibitor κB
  • MAC, mid upper arm circumference
  • TSF, triceps skinfold thickness
  • AMA, arm muscle area
  • EPA, eicosapentaenoic acid
  • EORTC QLQ, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
  • thalidomide
  • cachexia
  • pancreatic cancer
  • weight loss
  • randomised controlled trial
View Full Text

Statistics from Altmetric.com

Footnotes

  • Conflict of interest: None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles